Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167072 | 1.00 | MAPT (0.60) | MAPTNR4A1KMT2ANPC1MEN1 | |
| SCHEMBL30646245 | 0.92 | TSHR (0.53) | MAPTNR4A1KMT2ANPC1MEN1 | |
| SCHEMBL11655575 | 0.92 | TSHR (0.53) | MAPTNR4A1KMT2ANPC1MEN1 | |
| SCHEMBL11821808 | 0.89 | NR4A1 (0.61) | MAPTNR4A1KMT2ANPC1MEN1 | |
| SCHEMBL10430132 | 0.88 | TSHR (0.59) | MAPTNR4A1NPC1KDM4ETP53 | |
| SCHEMBL6606988 | 0.86 | TSHR (0.62) | MAPTNR4A1NPC1KDM4ETP53 | |
| SCHEMBL9448760 | 0.86 | TSHR (0.62) | MAPTNR4A1NPC1KDM4ETP53 | |
| SCHEMBL10187313 | 0.84 | MAPT (0.53) | MAPTKMT2ANPC1MEN1KDM4E | |
| SCHEMBL8417912 | 0.84 | MAPT (0.68) | MAPTKMT2AMEN1KDM4ECA12 | |
| SCHEMBL11806365 | 0.84 | MAPT (0.53) | MAPTKMT2ANPC1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103601685-A | Preparation method of oxibendazole | CHANGZHOU YABANG QH PHARMACHEM CO LTD | 2014-02-26 | — | — | CN | claimed |
| CN-102250012-B | Process for preparing benzimidazole insectifuge oxibendazole | JIANGSU BAOZONG BAODA PHARMACEUTICAL CO LTD | 2012-12-19 | — | — | CN | claimed |
| CN-102250012-A | Process for preparing benzimidazole insectifuge oxibendazole | JIANGSU BAOZONG BAODA PHARMACEUTICAL CO LTD | 2011-11-23 | — | — | CN | claimed |
| WO-2023239007-A1 | BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR INFECTIOUS DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239007-A1 | BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR INFECTIOUS DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| CN-107709477-B | Durable architectural coatings comprising crosslinkable polymeric additives | 科慕埃弗西有限公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2015161014-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| CN-103601685-A | Preparation method of oxibendazole | CHANGZHOU YABANG QH PHARMACHEM CO LTD | 2014-02-26 | — | — | CN | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| CN-102250012-B | Process for preparing benzimidazole insectifuge oxibendazole | JIANGSU BAOZONG BAODA PHARMACEUTICAL CO LTD | 2012-12-19 | — | — | CN | disclosed |
| CN-102250012-A | Process for preparing benzimidazole insectifuge oxibendazole | JIANGSU BAOZONG BAODA PHARMACEUTICAL CO LTD | 2011-11-23 | — | — | CN | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| US-4321393-A | Method for preparing 2-cyanamidobenzimidazoles or 2-cyanamidobenzoxazoles | SMITHKLINE CORPORATION (US) | 1982-03-23 | — | — | US | disclosed |
| US-4285878-A | N-Phenyl-N'-cyano-O-phenylisoureas | SMITHKLINE CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | MAPT 1907/4885NR4A1 3931/4885KMT2A 3742/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | MAPT 2281/4885NR4A1 531/4885KMT2A 3768/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | MAPT 5/4885NR4A1 3458/4885KMT2A 2881/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | MAPT 5/4885NR4A1 3458/4885KMT2A 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.